Enable Accessibility Enable Accessibility

Press Releases and Position Statements

MARCH 15

Takeda and IDT Support Manufacturing of Johnson & Johnson’s COVID-19 Vaccine

MARCH 5

Takeda Submits New Drug Application to Import and Distribute Moderna’s COVID-19 Vaccine Candidate in Japan

FEBRUARY 24

Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax’ and Moderna’s COVID-19 Vaccine Candidates in Japan

JANUARY 21

Start of a Japanese Clinical Study of TAK-919, Moderna’s COVID-19 Vaccine Candidate

DECEMBER 2

COVID-19 and the Role of Diagnostic Testing for Asymptomatic and Pre-Symptomatic Individuals

DECEMBER 1

World’s Leading Life Science Companies Now Enrolling COMMUNITY, A Global Platform Trial For Hospitalized Patients with COVID-19

OCTOBER 29

Takeda Expands COVID-19 Vaccine Supply in Japan Through Partnership with Moderna and Government of Japan

OCTOBER 9

First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine

OCTOBER 1

19 Organizations from the Healthcare Community Unite to Form COVID-19 Testing Industry Consortium

AUGUST 7

Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan

AUGUST 3

Members of the COVID R&D Alliance and Quantum Leap Healthcare Collaborative Enroll First Patients in I-SPY COVID Trial

MAY 26

Racing Against Time, Medical Researchers, Life Science Companies and COVID-19 Survivors Launch National Campaign to Drive Blood Plasma Donation

MAY 7

CoVIg-19 Plasma Alliance Builds Strong Momentum Through Expanded Membership and Clinical Trial Collaboration

APRIL 6

Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy

MARCH 25

Takeda Research & Development and COVID-19

MARCH 23

Coronavirus and Product Supply

MARCH 4

Takeda Initiates Development of a Plasma-Derived Therapy for COVID-19